Logo image of LMNL

LIMINAL BIOSCIENCES INC (LMNL) Stock Fundamental Analysis

USA - NASDAQ:LMNL - CA53272L2021 - Common Stock

8.5 USD
+0.01 (+0.12%)
Last: 9/25/2023, 8:00:18 PM
Fundamental Rating

2

Taking everything into account, LMNL scores 2 out of 10 in our fundamental rating. LMNL was compared to 534 industry peers in the Biotechnology industry. LMNL has a bad profitability rating. Also its financial health evaluation is rather negative. LMNL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

LMNL had positive earnings in the past year.
In the past year LMNL has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: LMNL reported negative net income in multiple years.
In the past 5 years LMNL always reported negative operating cash flow.
LMNL Yearly Net Income VS EBIT VS OCF VS FCFLMNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

LMNL's Return On Assets of 1.46% is amongst the best of the industry. LMNL outperforms 93.73% of its industry peers.
LMNL's Return On Equity of 2.16% is amongst the best of the industry. LMNL outperforms 93.73% of its industry peers.
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMNL Yearly ROA, ROE, ROICLMNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

LMNL has a Profit Margin of 94.11%. This is amongst the best in the industry. LMNL outperforms 99.67% of its industry peers.
The Operating Margin and Gross Margin are not available for LMNL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMNL Yearly Profit, Operating, Gross MarginsLMNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 2K -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMNL has about the same amount of shares outstanding.
Compared to 1 year ago, LMNL has an improved debt to assets ratio.
LMNL Yearly Shares OutstandingLMNL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
LMNL Yearly Total Debt VS Total AssetsLMNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -45.25, LMNL is not doing good in the industry: 95.71% of the companies in the same industry are doing better.
LMNL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
LMNL has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -45.25
ROIC/WACCN/A
WACC7.87%
LMNL Yearly LT Debt VS Equity VS FCFLMNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 2.78 indicates that LMNL has no problem at all paying its short term obligations.
LMNL has a worse Current ratio (2.78) than 74.75% of its industry peers.
LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LMNL (2.78) is worse than 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
LMNL Yearly Current Assets VS Current LiabilitesLMNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

LMNL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -99.10%.
Looking at the last year, LMNL shows a very negative growth in Revenue. The Revenue has decreased by -12.92% in the last year.
The Revenue for LMNL have been decreasing by -59.99% on average. This is quite bad
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%

3.2 Future

LMNL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -230.98% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LMNL Yearly Revenue VS EstimatesLMNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LMNL Yearly EPS VS EstimatesLMNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 77.27, which means the current valuation is very expensive for LMNL.
Compared to the rest of the industry, the Price/Earnings ratio of LMNL indicates a rather cheap valuation: LMNL is cheaper than 93.89% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of LMNL to the average of the S&P500 Index (26.91), we can say LMNL is valued expensively.
The Forward Price/Earnings Ratio is negative for LMNL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 77.27
Fwd PE N/A
LMNL Price Earnings VS Forward Price EarningsLMNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMNL Per share dataLMNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A cheap valuation may be justified as LMNL's earnings are expected to decrease with -230.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LMNL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIMINAL BIOSCIENCES INC

NASDAQ:LMNL (9/25/2023, 8:00:18 PM)

8.5

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-07 2023-11-07/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.82M
Revenue(TTM)492.00K
Net Income(TTM)463.00K
Analysts43.33
Price Target7.65 (-10%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 77.27
Fwd PE N/A
P/S 55.26
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)0.11
EY1.29%
EPS(NY)-8.96
Fwd EYN/A
FCF(TTM)-11.29
FCFYN/A
OCF(TTM)-11.29
OCFYN/A
SpS0.15
BVpS6.71
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.11%
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.29%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -45.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)12.21%
Cap/Depr(5y)35.07%
Cap/Sales(3y)46.16%
Cap/Sales(5y)49.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A

LIMINAL BIOSCIENCES INC / LMNL FAQ

What is the ChartMill fundamental rating of LIMINAL BIOSCIENCES INC (LMNL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LMNL.


What is the valuation status of LIMINAL BIOSCIENCES INC (LMNL) stock?

ChartMill assigns a valuation rating of 1 / 10 to LIMINAL BIOSCIENCES INC (LMNL). This can be considered as Overvalued.


Can you provide the profitability details for LIMINAL BIOSCIENCES INC?

LIMINAL BIOSCIENCES INC (LMNL) has a profitability rating of 3 / 10.


What are the PE and PB ratios of LIMINAL BIOSCIENCES INC (LMNL) stock?

The Price/Earnings (PE) ratio for LIMINAL BIOSCIENCES INC (LMNL) is 77.27 and the Price/Book (PB) ratio is 1.27.